利伐沙班治疗青斑样血管病12例

Therapeutic effect of rivaroxaban on livedoid vasculopathy in 12 cases

目的探讨利伐沙班治疗青斑样血管病的临床疗效和安全性。方法 12例青斑样血管病患者,均口服利伐沙班10 mg/次,1次/d,连续治疗12周。采用视觉模拟评分(visual analogue scale, VAS)评估治疗前及治疗4、8、12周疼痛程度,治疗12周评价治疗有效率,记录治疗过程中不良反应发生情况,随访12个月观察皮疹复发情况。结果治疗后12例皮疹逐渐消退,萎缩性瘢痕及色素沉着均减轻,溃疡逐渐愈合;治疗前及治疗后4、8、12周VAS评分[(4.99±0.32)、(2.35±0.24)、(0.92±0.36)、(0.18±0.11)分]依次降低(P<0.05);治疗12周时有效率为100.00%;12例均未出现不良反应;随访12个月皮疹均未复发。结论利伐沙班治疗青斑样血管病疗效确切、不易复发,且较安全。

Objective To investigate the therapeutic effect and safety of rivaroxaban in the treatment of livedoid vasculopathy(LV).Methods Twelve patients with LV were treated with rivaroxaban 10mg once daily,totally for 12 weeks.The visual analogue scale(VAS)was used to evaluate the pain degree before treatment,and after 4-,8-and 12-week treatment.The 12-week effective rate was calculated.The adverse reactions during treatment were recorded.All patients were followed up for 12months to observe the relapse of rash.Results After treatment,the rash subsided gradually in 12patients,atrophic scar and pigmentation were relieved,and ulcer was gradually healed.The VAS score decreased gradually before treatment and after 4-,8-and 12-week treatment(4.99±0.32,2.35±0.24,0.92±0.36, 0.18±0.11)in turns(P<0.05).The 12-week effective rate was 100.00%.No adverse reactions or relapse of rash occurred in 12-month follow-up.Conclusion Rivaroxaban is safe and effective for LV,with no relapse.